Welcome to our dedicated page for Protalix Biother news (Ticker: PLX), a resource for investors and traders seeking the latest updates and insights on Protalix Biother stock.
News and updates for Protalix BioTherapeutics, Inc. (PLX) center on its activities as a biopharmaceutical company focused on rare disease therapeutics and recombinant proteins produced with its proprietary ProCellEx® plant cell-based expression system. This page aggregates company press releases, financial announcements and clinical program updates that reflect how Protalix is developing and commercializing enzyme replacement therapies and advancing its pipeline.
Investors and followers of PLX can find coverage of commercial performance for the company’s approved products, including Elfabrio® for Fabry disease and Elelyso® (taliglucerase alfa) for Gaucher disease, supplied to partners such as Chiesi, Pfizer and Fiocruz in Brazil. News items also describe how these established revenue streams support Protalix’s research and development efforts.
Another key theme in Protalix news is pipeline progress. The company regularly reports on PRX–115, a plant cell-expressed recombinant PEGylated uricase for uncontrolled gout, including Phase 1 data and regulatory milestones like the submission of an IND to the FDA for a planned Phase 2 trial. Updates also cover PRX–119, a long-acting DNase I candidate for NETs-related and rare renal diseases, and the company’s collaboration with Secarna Pharmaceuticals to discover antisense oligonucleotide therapies for rare kidney indications.
Regulatory and corporate developments appear frequently in PLX news, such as EMA evaluations of new dosing regimens for Elfabrio, inclusion in the Russell 3000® and 2000® Indexes, at-the-market equity program amendments, executive appointments and outcomes of stockholder meetings or legal matters. Bookmark this page to follow how Protalix’s commercial partnerships, clinical trials and strategic collaborations evolve over time.
Protalix BioTherapeutics, Inc. will announce its financial results for the first quarter of 2024 on May 10, 2024, along with a business and clinical update. The company focuses on developing and commercializing recombinant therapeutic proteins. Investors can join the conference call and webcast to discuss the results and recent developments. The call details are provided for easy access.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.